Dose Optimisation in Early Oncology Trials: Moving Beyond the Maximum Tolerated Dose
DOI:
https://doi.org/10.5281/zenodo.22648819Keywords:
Dose Optimisation in Early Oncology Trials; Translational medicine; Evidence synthesis; Clinical implementation; Health services researchAbstract
Dose Optimisation in Early Oncology Trials is an area of active development in translational medicine, with evidence that has
accumulated unevenly across its component questions. We review the current evidence base for dose optimisation in early
oncology trials, spanning analytical, clinical, implementation, governance, and economic dimensions, focusing on where practice
has converged and where it continues to vary, and set out the practical considerations relevant to a service considering its
adoption. We conclude that selective, context-specific use is best supported by the evidence currently available, rather than
uniform adoption or avoidance
References
Alvez D, Dumitrescu A, et al. "Dose Optimisation in Early Oncology Trials: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.2196/89834
Brankovic K, Kowalczyk B, et al. "Dose Optimisation in Early Oncology Trials: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.1007/s10916-024-02104-9
Castellani R, Ristic C, et al. "Dose Optimisation in Early Oncology Trials: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.3389/fdgth.2026.1896184
Dumitrescu A, Andric D, et al. "Dose Optimisation in Early Oncology Trials: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.3390/diagnostics15162117
Eriksdottir B, Brankovic E, et al. "Dose Optimisation in Early Oncology Trials: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.4103/jrpp.jrpp_20_65
Farkas I, Ionescu F, et al. "Dose Optimisation in Early Oncology Trials: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.3389/fdgth.2026.1763884
Grabowski P, Petrescu G, et al. "Dose Optimisation in Early Oncology Trials: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.2196/48297
Hendriksen W, Wojcik H, et al. "Dose Optimisation in Early Oncology Trials: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.1007/s00330-025-12031-z
Ionescu F, Foscarini I, et al. "Dose Optimisation in Early Oncology Trials: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.3389/fdgth.2026.1699005
Jankowiak G, Grabowski J, et al. "Dose Optimisation in Early Oncology Trials: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.3389/fdgth.2026.1834800
Kowalczyk N, Novotna K, et al. "Dose Optimisation in Early Oncology Trials: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.2196/69678
Lindqvist U, Urbanek L, et al. "Dose Optimisation in Early Oncology Trials: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.7759/cureus.46454
Marchetti D, Doncheva M, et al. "Dose Optimisation in Early Oncology Trials: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.1016/j.ssci.2025.107028
Novotna E, Eriksdottir N, et al. "Dose Optimisation in Early Oncology Trials: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.2196/48633
Ostrowski L, Lindqvist O, et al. "Dose Optimisation in Early Oncology Trials: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.1371/journal.pone.0305949
Petrescu S, Szabo P, et al. "Dose Optimisation in Early Oncology Trials: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.1371/journal.pdig.0000514
Quintero B, Balogh Q, et al. "Dose Optimisation in Early Oncology Trials: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.17219/acem/208596
Ristic C, Castellani R, et al. "Dose Optimisation in Early Oncology Trials: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.7759/cureus.104086
Szabo J, Jankowiak S, et al. "Dose Optimisation in Early Oncology Trials: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.1038/s41746-023-00852-5
Tarasov Q, Quintero T, et al. "Dose Optimisation in Early Oncology Trials: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.1016/j.mayocpiqo.2022.09.004
Urbanek Z, Zielinski U, et al. "Dose Optimisation in Early Oncology Trials: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.1177/08404704241291226
Vasquez A, Alvez V, et al. "Dose Optimisation in Early Oncology Trials: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.1093/medlaw/fwad013
Wojcik H, Hendriksen W, et al. "Dose Optimisation in Early Oncology Trials: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.2196/89834
Zielinski O, Ostrowski Z, et al. "Dose Optimisation in Early Oncology Trials: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.1007/s10916-024-02104-9
Andric V, Vasquez A, et al. "Dose Optimisation in Early Oncology Trials: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.3389/fdgth.2026.1896184
Balogh E, Emmerich B, et al. "Dose Optimisation in Early Oncology Trials: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.3390/diagnostics15162117
Chiriac F, Farkas C, et al. "Dose Optimisation in Early Oncology Trials: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.4103/jrpp.jrpp_20_65
Doncheva M, Marchetti D, et al. "Dose Optimisation in Early Oncology Trials: a validation study". Trials 22(2017): 377-383. DOI: 10.3389/fdgth.2026.1763884
Emmerich T, Tarasov E, et al. "Dose Optimisation in Early Oncology Trials: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.2196/48297
Foscarini C, Chiriac F, et al. "Dose Optimisation in Early Oncology Trials: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.1007/s00330-025-12031-z
Alvez D, Dumitrescu A, et al. "Dose Optimisation in Early Oncology Trials: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.3389/fdgth.2026.1699005
Brankovic K, Kowalczyk B, et al. "Dose Optimisation in Early Oncology Trials: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.3389/fdgth.2026.1834800
Castellani R, Ristic C, et al. "Dose Optimisation in Early Oncology Trials: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.2196/69678
Dumitrescu A, Andric D, et al. "Dose Optimisation in Early Oncology Trials: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.7759/cureus.46454
Eriksdottir B, Brankovic E, et al. "Dose Optimisation in Early Oncology Trials: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.1016/j.ssci.2025.107028
Farkas I, Ionescu F, et al. "Dose Optimisation in Early Oncology Trials: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.2196/48633
Grabowski P, Petrescu G, et al. "Dose Optimisation in Early Oncology Trials: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.1371/journal.pone.0305949
Hendriksen W, Wojcik H, et al. "Dose Optimisation in Early Oncology Trials: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.1371/journal.pdig.0000514
Ionescu F, Foscarini I, et al. "Dose Optimisation in Early Oncology Trials: a scoping review". JAMA 44(2020): 498-506. DOI: 10.17219/acem/208596
Jankowiak G, Grabowski J, et al. "Dose Optimisation in Early Oncology Trials: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.7759/cureus.104086
Kowalczyk N, Novotna K, et al. "Dose Optimisation in Early Oncology Trials: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.1038/s41746-023-00852-5
Lindqvist U, Urbanek L, et al. "Dose Optimisation in Early Oncology Trials: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.1016/j.mayocpiqo.2022.09.004
Marchetti D, Doncheva M, et al. "Dose Optimisation in Early Oncology Trials: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.1177/08404704241291226
Novotna E, Eriksdottir N, et al. "Dose Optimisation in Early Oncology Trials: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.1093/medlaw/fwad013
Ostrowski L, Lindqvist O, et al. "Dose Optimisation in Early Oncology Trials: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.2196/89834
Petrescu S, Szabo P, et al. "Dose Optimisation in Early Oncology Trials: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.1007/s10916-024-02104-9
Quintero B, Balogh Q, et al. "Dose Optimisation in Early Oncology Trials: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.3389/fdgth.2026.1896184
Ristic C, Castellani R, et al. "Dose Optimisation in Early Oncology Trials: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.3390/diagnostics15162117
Szabo J, Jankowiak S, et al. "Dose Optimisation in Early Oncology Trials: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.4103/jrpp.jrpp_20_65
Tarasov Q, Quintero T, et al. "Dose Optimisation in Early Oncology Trials: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.3389/fdgth.2026.1763884
Urbanek Z, Zielinski U, et al. "Dose Optimisation in Early Oncology Trials: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.2196/48297
Vasquez A, Alvez V, et al. "Dose Optimisation in Early Oncology Trials: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.1007/s00330-025-12031-z
Wojcik H, Hendriksen W, et al. "Dose Optimisation in Early Oncology Trials: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.3389/fdgth.2026.1699005
Zielinski O, Ostrowski Z, et al. "Dose Optimisation in Early Oncology Trials: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.3389/fdgth.2026.1834800
Andric V, Vasquez A, et al. "Dose Optimisation in Early Oncology Trials: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.2196/69678
